“…There are other oligomers that can also be formed in the synthesis of BNZ drug substance and which can be determined as degradation impurities with the specified specification level by HPLC (Katakam et al, 2020d), and these components of interest are found by interference, co-elution and poor selectivity by this methodology owing to the consecutive elution of monomer units from n = 2 to n = 17. In the literature, the particular identification and characterization of poly(ethylene glycol) (PEG) and PEGylated products by LC-MS with post-column addition of amines (Huang et al, 2009) and by liquid chromatography on monolithic silica rods (Brunzel et al, 2018) with other spectroscopic techniques (Barman et al, 2009;Kimac et al, 2020;Sayers et al, 2014;Zhang et al, 2014) has been published. There is some published literature on the quantitative determination of the BNZ drug substance in human plasma and pharmacokinetic studies (Lin et al, 1996;Man et al, 2019), which is not specific to quantitation of the subject component of interest.…”